Diverse Cohort Reveals Universal Genetic Variations Impacting Prescription Drug Metabolism

The assumption that genetic variations affecting medication metabolism are rare anomalies has been overturned by one of the most diverse genomic studies ever conducted. An analysis of nearly 100,000 participants found that every single individual carries at least one gene variant capable of altering their response to prescription drugs.[1][4]

The findings, published in Science Translational Medicine, represent a major milestone in the transition toward precision medicine. By pairing whole-genome sequencing with longitudinal electronic health records, researchers evaluated 16 well-established pharmacogenes across 98,590 Americans to determine how commonly these variations occur.[3][4]

Historically, the field of pharmacogenomics has been constrained by a persistent lack of ancestral diversity. The vast majority of foundational genetic data was drawn from populations of European descent, leaving significant knowledge gaps regarding how other groups process common medications.[3]

"The limited diversity of racial and ethnic groups in early studies is a challenge in genetic research and skews risk estimates," said Philip E. Empey, senior author and researcher at the University of Pittsburgh. He noted that relying on homogeneous data creates inherent risks for underrepresented patients.[1]

Empey noted that the National Institutes of Health’s All of Us Research Program was intentionally designed to close these gaps. The initiative actively recruits individuals from a wide range of backgrounds and life experiences to build a more accurate, inclusive picture of human health.[1]

Unprecedented Cohort Diversity

To conduct the analysis, the research team utilized data from the All of Us cohort, which provided an unprecedented level of genomic diversity. The study population included 48,112 participants of European ancestry, 23,179 of African ancestry, 15,133 of Americas ancestry, and 2,199 of East Asian ancestry.[2][4]

Within this diverse group, the molecular analyses demonstrated that genetic variation in drug-processing genes is universally present. Fully 100 percent of the cohort harbored at least one variant within the 16 evaluated pharmacogenes, with a median of nine variants per person.[1][3]

The human body relies on a complex network of enzymes, primarily produced in the liver, to break down pharmaceutical compounds. When a genetic variant alters the shape or efficiency of these enzymes, the standard recommended dosage of a drug can become either dangerously potent or entirely ineffective.[4]

These variants do not necessarily cause disease, but they dictate how efficiently the body metabolizes specific chemical compounds. Depending on the variant, a patient might clear a drug from their system too rapidly for it to take effect, or metabolize it so slowly that toxic levels accumulate.[4]

The research team also identified over 17,000 novel genetic variants during their comprehensive analysis. They reported the frequency of known medication-linked variants across multiple ancestry groups where these rates had never been previously estimated, significantly expanding the field's foundational knowledge base.[1][4]

Real-World Clinical Impact

The universal presence of these genetic variations translates directly into everyday clinical practice. When scientists correlated the genetic findings with participants' medical histories, they discovered that 24.4 percent of the cohort had documented exposure to a medication directly affected by their specific gene variants.[3][4]

The most common medications identified in the review are widely used across the healthcare system for routine conditions. They include the anti-nausea drug ondansetron, the anti-inflammatory ibuprofen, and the cholesterol-lowering medication atorvastatin, all of which are prescribed to millions of patients annually.[1]

Acid reflux treatments, specifically omeprazole and pantoprazole, were also among the most frequently prescribed drugs impacted by these genetic differences. For patients with certain variants, standard doses of these medications may provide no relief, requiring clinicians to blindly adjust dosages without understanding the underlying biological cause.[1][4]

Individuals who are genetically classified as ultra-rapid metabolizers process certain medications so quickly that the drug is eliminated before it can exert any therapeutic effect. Conversely, poor metabolizers lack the necessary enzyme function, leading to a buildup of the drug that can trigger severe adverse reactions.[4]

"While many things impact how a patient responds to medication, our research tells us that genetics could be a factor for a large proportion of patients," Empey explained. He emphasized that the data points to the immediate value of precision medicine in routine prescribing.[1]

Correcting Historical Blind Spots

Crucially, the study revealed that variant frequencies in underrepresented groups differed substantially from the reference data that currently informs standard clinical practice. These deviations expose serious blind spots created by relying on historically homogeneous cohorts to develop clinical pharmacogenomics guidelines.[3][4]

For example, the frequencies observed for key pharmacogenes, such as SLCO1B1 within the African ancestry group, deviated markedly from earlier datasets. The SLCO1B1 gene regulates how the liver absorbs statins, and inaccurate frequency data can lead to an underestimation of toxicity risks in specific populations.[3][4]

By expanding genetic sequencing to historically underrepresented populations, researchers can resolve these substantial gaps in pharmacogenomic knowledge. The updated frequencies provide a much more accurate picture of medication-linked genetic risks, allowing for safer prescribing guidelines across all ancestries.[3]

Ángel Carracedo Álvarez, a genomic medicine expert at the University of Santiago de Compostela, noted that the high prevalence of actionable variants is highly relevant for modern healthcare. He suggested that the findings strongly support the need for cost-effectiveness studies regarding preemptive genetic testing.[2]

Carracedo Álvarez added that pharmacogenetic screening strategies and automated alerts within electronic health records could soon become essential clinical tools. These systems would automatically warn a physician if they attempt to prescribe a medication that conflicts with a patient's genetic profile.[2]

The Future of Prescribing

The integration of this diverse dataset into clinical knowledge bases is expected to accelerate the adoption of personalized prescribing. More than 300 medications currently have information on their labels regarding genetic variant interactions, indicating where testing can guide safe usage.[1][4]

One prominent example is a chemotherapy drug used for colon cancer that can cause severe, life-threatening toxicity in up to 8 percent of patients who carry specific genetic variants. Because the risk is well-documented, those patients are now proactively tested before treatment begins.[1]

The goal of broad pharmacogenomic implementation is to bring that same level of preemptive safety to everyday medications. As sequencing costs continue to fall and data availability increases, experts anticipate that checking a patient's genetic profile will become as routine as checking for drug allergies.[1]

However, realizing this vision will require significant updates to healthcare infrastructure. Clinics must develop systems capable of securely storing genomic data, and physicians will need ongoing education to accurately interpret pharmacogenomic alerts during short patient consultations.[2]

Furthermore, genetic testing must be integrated seamlessly into existing electronic health records to prevent alert fatigue among healthcare providers. If systems generate too many warnings for minor genetic interactions, clinicians may begin to ignore the alerts, undermining the safety benefits of the screening program.[2]

Researchers also acknowledge that genetics is only one piece of the prescribing puzzle. A patient's age, kidney function, diet, and concurrent medications all interact with their genetic baseline, meaning that pharmacogenomic data must be used to inform clinical judgment rather than replace it entirely.[1][2]

"As All of Us achieves its goals to recruit participants from groups whose health outcomes have not been extensively studied in biomedical research, we expect that broad representation will continue to expand," the study authors concluded.[3][4]

They anticipate this growing dataset will increasingly increase the value of precision medicine. By preventing adverse drug reactions before they occur, universal pharmacogenomic insights have the potential to fundamentally improve the health and safety of diverse populations.[3][4]